Seagen (SGEN) Stock

Seagen (SGEN) and Astellas Pharma announce that the FDA has accepted the label expansion-seeking application for the Padcev/Keytruda combo under priority review to treat first-line bladder cancer.

Seagen reported mixed third quarter earnings, with revenue outperforming expectations on strong product sales growth as earnings fell short of estimates. The cancer-focused biotechnology company which is being acquired by Pfizer reported revenue of $649 million for 3Q.

Biotech stock Seagen Inc (NASDAQ:SGEN) scored an all-time high of $215.04 today, building on a Friday breakout from a consolidation between $204 and $210.

Seagen (SGEN) announces positive top-line results from its late-stage study of the Padcev/Keytruda combo in the treatment of adult patients with metastatic bladder cancer. The stock of the company rises 3.5%.

Seagen (SGEN) announces positive top-line results from its breast cancer study evaluating Tuksya in combination with Roche's Kadcyla.

Seagen said on Wednesday its breast cancer therapy in combination with Roche's Kadcyla helped extend the time patients lived without their disease progressing in a late-stage trial.

Seagen (NASDAQ: SGEN ) stock is slipping on Tuesday after one of the company's directors sold some of their shares. According to a filing with the Securities and Exchange Commission (SEC), Seagen director Daniel Welch sold 1,864 shares of SGEN stock.

Seattle Genetics (SGEN) came out with a quarterly loss of $0.93 per share versus the Zacks Consensus Estimate of a loss of $0.82. This compares to loss of $0.74 per share a year ago.

The FDA grants accelerated approval to Seagen (SGEN) and partner, Astellas' combination therapy of Padcev with Merck's Keytruda for the treatment of first and second-line metastatic urothelial cancer.